Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Trodelvy

- PMLiVE

Sovaldi deal for developing world ‘falls short’

Critics claim Gilead have allowed Indian companies to set their own price

- PMLiVE

Takeda: No link between Actos and bladder cancer

Ten-year study backs safety of diabetes drug

The seven letter debate that is Sovaldi

Reimbursement of high cost hepatitis C drugs raise difficult issues

Gilead Sciences

Sovaldi stumbles as NICE assesses hep C drug’s price

Gilead must provide much more cost-effectiveness information

- PMLiVE

J&J files HIV combination in Europe

Seeks approval for fixed-dose tablet containing Prezista and Gilead’s cobicistat

- PMLiVE

Kidney cancer campaign launches in UK

The ‘Be Clear on Cancer’ campaign is aimed at raising awareness of the symptoms of bladder and kidney cancers

- PMLiVE

EMA backs drugs from Novo, Otsuka, AZ, Janssen, GSK

Nine new branded medicines recommended for use in Europe

- PMLiVE

FDA refuses to back Gilead’s two HIV drugs

Agency questions quality of testing procedures for elvitegravir and cobicistat

- PMLiVE

EU recommendations for Gilead, Ariad and Baxter drugs

EMA backs use of HyQvia, Iclusig and Stribild

- PMLiVE

Gilead recalls Vistide due to foreign particles

Affected batch of AIDS symptom treatment sold in the US, Europe and Canada

- PMLiVE

Gilead $1bn antibody deal with MacroGenics

Joins Boehringer and Servier in use of US biotech’s DART technology

- PMLiVE

Gilead expands in cancer with $510m YM BioSciences deal

Lands JAK inhibitor CYT387

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links